Liraglutide reduces tau hyperphosphorylation in both AD (Yang et al., 2013; Chen et al., 2017) and T2D models (Yang et al., 2013; Ma et al., 2015), indicating another feasible underlying mechanism for its neuroprotective role. This evidence concerns the gene MAPT and type 2 diabetes mellitus.